These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

144 related items for PubMed ID: 8897561

  • 1. Long-term therapy with enalapril in patients with nephrotic-range proteinuria.
    Proesmans W, Wambeke IV, Dyck MV.
    Pediatr Nephrol; 1996 Oct; 10(5):587-9. PubMed ID: 8897561
    [Abstract] [Full Text] [Related]

  • 2. Enalapril: antiproteinuric effect in children with nephrotic syndrome.
    Lama G, Luongo I, Piscitelli A, Salsano ME.
    Clin Nephrol; 2000 Jun; 53(6):432-6. PubMed ID: 10879662
    [Abstract] [Full Text] [Related]

  • 3. Enalapril and prednisone in children with nephrotic-range proteinuria.
    Delucchi A, Cano F, Rodriguez E, Wolff E, Gonzalez X, Cumsille MA.
    Pediatr Nephrol; 2000 Oct; 14(12):1088-91. PubMed ID: 11045392
    [Abstract] [Full Text] [Related]

  • 4. Efficacy of enalapril in the treatment of steroid resistant idiopathic nephrotic syndrome.
    Prasher PK, Varma PP, Baliga KV.
    J Assoc Physicians India; 1999 Feb; 47(2):180-2. PubMed ID: 10999084
    [Abstract] [Full Text] [Related]

  • 5. Renoprotective effect of small doses of losartan and enalapril in patients with primary glomerulonephritis. Short-term observation.
    Tylicki L, Rutkowski P, Renke M, Rutkowski B.
    Am J Nephrol; 2002 Feb; 22(4):356-62. PubMed ID: 12169868
    [Abstract] [Full Text] [Related]

  • 6. Losartan and enalapril are comparable in reducing proteinuria in children with Alport syndrome.
    Webb NJ, Shahinfar S, Wells TG, Massaad R, Gleim GW, McCrary Sisk C, Lam C.
    Pediatr Nephrol; 2013 May; 28(5):737-43. PubMed ID: 23207876
    [Abstract] [Full Text] [Related]

  • 7. Enalapril in paediatric patients with Alport syndrome: 2 years' experience.
    Proesmans W, Knockaert H, Trouet D.
    Eur J Pediatr; 2000 Jun; 159(6):430-3. PubMed ID: 10867848
    [Abstract] [Full Text] [Related]

  • 8. Enalapril in children with Alport syndrome.
    Proesmans W, Van Dyck M.
    Pediatr Nephrol; 2004 Mar; 19(3):271-5. PubMed ID: 14745635
    [Abstract] [Full Text] [Related]

  • 9. Nephropathy of cyanotic congenital heart disease: clinical characteristics and effectiveness of an angiotensin-converting enzyme inhibitor.
    Fujimoto Y, Matsushima M, Tsuzuki K, Okada M, Shibata M, Yanase Y, Usui K, Nagashima M.
    Clin Nephrol; 2002 Aug; 58(2):95-102. PubMed ID: 12227694
    [Abstract] [Full Text] [Related]

  • 10. ACE inhibition improves glomerular size selectivity in patients with idiopathic membranous nephropathy and persistent nephrotic syndrome.
    Ruggenenti P, Mosconi L, Vendramin G, Moriggi M, Remuzzi A, Sangalli F, Remuzzi G.
    Am J Kidney Dis; 2000 Mar; 35(3):381-91. PubMed ID: 10692263
    [Abstract] [Full Text] [Related]

  • 11. Angiotensin converting enzyme inhibitor therapy in children with Alport syndrome: effect on urinary albumin, TGF-beta, and nitrite excretion.
    Adler L, Mathew R, Futterweit S, Frank R, Gauthier BG, Kashtan CE, Trachtman H.
    BMC Nephrol; 2002 Feb 14; 3():2. PubMed ID: 11869456
    [Abstract] [Full Text] [Related]

  • 12. Losartan and enalapril are comparable in reducing proteinuria in children.
    Webb NJ, Shahinfar S, Wells TG, Massaad R, Gleim GW, Santoro EP, Sisk CM, Lam C.
    Kidney Int; 2012 Oct 14; 82(7):819-26. PubMed ID: 22739977
    [Abstract] [Full Text] [Related]

  • 13. Effects of telmisartan and enalapril on renoprotection in patients with mild to moderate chronic kidney disease.
    Nakamura T, Fujiwara N, Kawagoe Y, Sugaya T, Ueda Y, Koide H.
    Eur J Clin Invest; 2010 Sep 14; 40(9):790-6. PubMed ID: 20584070
    [Abstract] [Full Text] [Related]

  • 14. [Long-term effect of angiotensin-converting inhibitors in children with proteinuria].
    Camacho Díaz JA, Giménez Llort A, García García L, Jiménez González R.
    An Esp Pediatr; 2001 Sep 14; 55(3):219-24. PubMed ID: 11676896
    [Abstract] [Full Text] [Related]

  • 15. Prevalence and pathologic features of sickle cell nephropathy and response to inhibition of angiotensin-converting enzyme.
    Falk RJ, Scheinman J, Phillips G, Orringer E, Johnson A, Jennette JC.
    N Engl J Med; 1992 Apr 02; 326(14):910-5. PubMed ID: 1542341
    [Abstract] [Full Text] [Related]

  • 16. Enalapril treatment of proteinuria in normotensive children.
    Sasinka MA, Podracka L, Boor A, Jurkovic I, Mitro A, Kovacs L.
    Bratisl Lek Listy; 1999 Sep 02; 100(9):476-80. PubMed ID: 10645036
    [Abstract] [Full Text] [Related]

  • 17. Angiotensin-converting enzyme inhibition in nondiabetic progressive renal insufficiency: a controlled double-blind trial.
    Ihle BU, Whitworth JA, Shahinfar S, Cnaan A, Kincaid-Smith PS, Becker GJ.
    Am J Kidney Dis; 1996 Apr 02; 27(4):489-95. PubMed ID: 8678058
    [Abstract] [Full Text] [Related]

  • 18. Reduction of proteinuria by angiotensin converting enzyme inhibition.
    Heeg JE, de Jong PE, van der Hem GK, de Zeeuw D.
    Kidney Int; 1987 Jul 02; 32(1):78-83. PubMed ID: 3041097
    [Abstract] [Full Text] [Related]

  • 19. Angiotensin-converting enzyme inhibition ameliorates the defect in glomerular size selectivity in hyponatremic hypertensive syndrome.
    Remuzzi A, Schieppati A, Battaglia C, Remuzzi G.
    Am J Kidney Dis; 1989 Sep 02; 14(3):170-7. PubMed ID: 2476029
    [Abstract] [Full Text] [Related]

  • 20. Renoprotection by ACE inhibitors after severe hemolytic uremic syndrome.
    Van Dyck M, Proesmans W.
    Pediatr Nephrol; 2004 Jun 02; 19(6):688-90. PubMed ID: 15064939
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.